期刊文献+

阿托伐他汀对急性冠脉综合征患者血清基质金属蛋白酶-9及其组织抑制因子-1的影响 被引量:7

原文传递
导出
摘要 目的 探讨阿托伐他汀对急性冠脉综合征(ACS)患者基质金属蛋白酶-9(MMP-9)及其组织抑制因子1(TIMP-1)表达的影响.方法 ACS患者124例按治疗方法不同分组:常规治疗为对照组,在常规治疗基础上加用阿托伐他汀为治疗组.观察两组治疗前后MMP-9、TIMP-1的变化.结果 治疗3周后治疗组血清MMP-9水平与对照组治疗后相比明显下降,血清TIMP-1水平明显升高,MMP-9/TIMP-1值明显降低(均P〈0.05).结论 阿托伐他汀可明显降低MMP-9/TIMP-1值,从而减少炎性反应,稳定斑块,改善预后,值得临床推广使用.
出处 《中国基层医药》 CAS 2010年第19期2653-2654,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献8

二级参考文献53

  • 1曹明艳,吕新华,陈雁斌,廖昆.急性冠脉综合征高敏C反应蛋白浓度变化及洛伐他汀的早期干预治疗[J].实用临床医药杂志,2005,9(7):88-89. 被引量:3
  • 2Martey CA,Pollock SJ,Turner CK,et al.Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts:implications for lung inflammation and cancer.Am J physiol Lung Cell Mol physiol,2004,287(5):L981.
  • 3Linton MF,Fazio S.Cyclooxygenase-2 and atherosclerosis.Currr Opin Lipidol,2002,13(5):497-504.
  • 4Szczeklik W,Sanak M,Postoff P,et al.Common polymorphisms of cyclooygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery diseac.Thromb Haemost,2008,100 (5):893-898.
  • 5Tjoelker H,Stafforini DM.Platelet-activating factor acetylhydrolases in health and disease.Biochim Biophys Acta,2000,1488 (1-2):102-103.
  • 6Blankenberg S,Stengel D,Rupprecht HJ,et al.Plasma PAF-acetylhydrolase in patients with coronary artery disease:results of a cross sectional analysis.J Lipid Res,2003 44(7):1381-1386.
  • 7Pearson TA,Mensah GA,Alexander Rw,et al.Markers of inflammarion and cardiovascular disease,application to clinical and public health practice:A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.Circulation,2003,107(3):499-511.
  • 8Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Nail Acad Sci USA, 2000, 97: 7458-7463.
  • 9Lutgens E, Cleutjens KBJM, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Nail Aced Sci. USA, 2000, 97: 7464-7469.
  • 10Kai H,Ikeda H, Yasukawa H, et al. Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. J Am Coll Cardiol , 1998,32:368-372.

共引文献306

同被引文献76

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部